Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Elna Van Der Ryst"'
Autor:
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0204099 (2018)
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind tr
Externí odkaz:
https://doaj.org/article/e5fed03ceb034b1a93eda448a932be0c
Autor:
John, Steytler, Charles, Craig, Elna, van der Ryst, Ben, Van Baelen, Jeremy, Nuttall, Neliëtte, van Niekerk, John, Mellors, Urvi, Parikh, Carole, Wallis
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
The Ring Study, a 2:1 randomized, double-blind, placebo-controlled Phase III trial, demonstrated 35.1% HIV-1 infection risk reduction among participants using the Dapivirine Vaginal Ring-004 (DVR). An open-label extension trial, DREAM, approximated a
Autor:
John, Steytler, Elna, van der Ryst, Charles, Craig, Ben, Van Baelen, Jeremy, Nuttall, Neliëtte, van Niekerk, John, Mellors, Urvi, Parikh, Carole, Wallis
Publikováno v:
Clin Infect Dis
BACKGROUND: Participants with human immunodeficiency virus (HIV) seroconversion in The Ring Study, a phase 3 trial of dapivirine vaginal ring (DVR), or in the open-label extension trial dapivirine ring extended access and monitoring (DREAM) were offe
Autor:
Charles Craig, Marilyn Lewis, Becky Jubb, Elna van der Ryst, Julie Mori, Barry Weatherley, Mike Westby, Phylinda L. S. Chan, Lynn McFadyen, Paul Simpson
Publikováno v:
Antiviral Chemistry & Chemotherapy
Antiviral Chemistry & Chemotherapy, Vol 27 (2019)
Antiviral Chemistry & Chemotherapy, Vol 27 (2019)
Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pre-existing CXCR4-using virus or through selection o
Autor:
Jayvant, Heera, Srinivas R, Valluri, Charles, Craig, Annie, Fang, Neal, Thomas, Ralph D, Meyer, Marilyn E, Lewis, Elna, van der Ryst, James, Demarest
Publikováno v:
The new microbiologica. 42(2)
Maraviroc (MVC, a CCR5 antagonist) is only fully active against CCR5 tropic [R5] HIV-1, and tropism testing is required prior to initiating treatment. The MODERN study prospectively compared genotypic (GTT) and phenotypic (Trofile®) tropism testing
Publikováno v:
Handbook of Biomarkers and Precision Medicine ISBN: 9780429202872
Handbook of Biomarkers and Precision Medicine
Handbook of Biomarkers and Precision Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdf6c2def49d049baf0b3df48c0929e6
https://doi.org/10.1201/9780429202872-32
https://doi.org/10.1201/9780429202872-32
Autor:
Charles Craig, Jonathan Toma, Mike Mosley, Wei Huang, Roy Mansfield, Mike Westby, David Robertson, Paul Simpson, Jeannette M. Whitcomb, Marilyn Lewis, Julie Mori, Elna van der Ryst
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0204099 (2018)
PLoS ONE
PLoS ONE
Detailed clonal phenotypic/genotypic analyses explored viral-escape mechanisms during maraviroc-based therapy in highly treatment-experienced participants from the MOTIVATE trials. To allow real-time assessment of samples while maintaining a blind tr
Autor:
Marinella Della Negra, Srinivas Rao Valluri, Carlo Giaquinto, Kulkanya Chokephaibulkit, Manoli Vourvahis, Ismail Mitha, Andrew Clark, Jan Fourie, Jayvant Heera, Charles Craig, Rebecca Yanhui Zhang-Roper, Lynn McFadyen, Elna van der Ryst, Muthuhadini Patience Mawela, Annie Fang
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the
Background: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the
Publikováno v:
Annals of the New York Academy of Sciences. 1346:7-17
Assays to identify infectious organisms are critical for diagnosis and enabling the development of therapeutic agents. The demonstration that individuals with a 32-bp deletion within the CCR5 locus were resistant to human immunodeficiency virus (HIV)
Autor:
Prudence Ive, Adriano Lazzarin, Geoffrey Mukwaya, Elna van der Ryst, David A. Cooper, Mariette E. Botes, Michael S. Saag, Robert Burnside, Edwin DeJesus, Jayvant Heera, Nathan Clumeck, Sharon Walmsley
Publikováno v:
AIDS (London, England)
Objective: Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial The